SEHK:2616
SEHK:2616Biotechs

EMA Backing for Sugemalimab Might Change the Case for Investing in CStone Pharmaceuticals (SEHK:2616)

Earlier this month, CStone Pharmaceuticals received a positive opinion from the European Medicines Agency's CHMP recommending approval of sugemalimab as a monotherapy for adults with unresectable stage III non-small cell lung cancer, following compelling Phase III data from the GEMSTONE-301 trial. This regulatory milestone further strengthens CStone’s clinical track record in oncology and highlights the company’s ability to advance immunotherapies addressing significant unmet needs in...
SEHK:1208
SEHK:1208Metals and Mining

MMG Limited (SEHK:1208): Evaluating Valuation Following Fresh Production Results and Updated Performance Metrics

MMG (SEHK:1208) has released its latest production results for the third quarter and year to date, giving investors an up-to-date look at output levels for copper, zinc, lead, and molybdenum. This fresh data can help gauge how the company is tracking against its operational goals and shapes expectations moving forward. See our latest analysis for MMG. The latest results come amid a surge in momentum for MMG, with a strong 79.4% 90-day share price return and an even more remarkable 187% gain...
SEHK:1519
SEHK:1519Logistics

How Investors Are Reacting To J&T Global Express (SEHK:1519) Surging Parcel Volumes and Double-Digit Growth

J&T Global Express Limited recently reported its operating results for the third quarter ended September 30, 2025, achieving a total parcel volume of approximately 7.68 billion, a 23.1% increase from the prior year, with all major markets experiencing double-digit growth, particularly in Southeast Asia and New Markets. The surge in parcel volumes highlights not only the strong momentum behind e-commerce in J&T’s core regions but also the company’s expanding footprint in emerging logistics...